Insulin resistance and diabetes: What is the role played by interleukins?;Insulinorésistance et diabète: Quel rôle jouent les interleukines?

Sang Thrombose Vaisseaux

Volumn 21, Issue 7, 2009, Pages 307-314

  Bastard, Jean Philippe ^a,b,c   Feve, Bruno ^a,d  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL TENON   (France)

^d BICÊTRE HOSPITAL   (France)

Author keywords

Adipokine; Adipose tissue; Cytokine; Diabetes; Insulin resistance; Interleukin; Obesity

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

DRUG EFFECT; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; SHORT SURVEY;

EID: 70049117330     PISSN: 09997385     EISSN: 19506104     Source Type: Journal    
DOI: 10.1684/stv.2009.0408     Document Type: Short Survey

References (54)

1. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867
2. Böni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin- 1β mRNA expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation. J Clin Endocrinol Metab 2008; 93: 4065-4074
3. Spranger J, Kroke A, Möhlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)- Postdam Study. Diabetes 2003; 52: 812-817 (Pubitemid 36323590)
4. Salmenniemi U, Ruotsalainen E, Pihlajamäki J, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004; 110: 3842-3848 (Pubitemid 40023983)
5. Juge-Aubry CE, Somm E, Chicheportiche R, et al. Regulatory effects of interleukin (IL)-1, interferon-beta, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue. J Clin Endocrinol Metab 2004; 89: 2652-2658 (Pubitemid 38766345)
6. He J, Usui I, Ishizuka K, et al. Inteleukin-1alpha inhibits insulin signalling with phosphorylating insulin receptor substrate-1 on serine residues in 3T3-L1 adipocytes. Mol Endocrinol 2006; 20: 114-124 (Pubitemid 43011674)
7. Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1beta-induced insulin resistance in adipocytes through downregulation of insulin receptor substrate-1 expression. Endocrinology 2007; 148: 241-251 (Pubitemid 46021456)
8. Lagathu C, Yvan-Charvet L, Bastard JP, et al. Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia 2006; 49: 2162-2173 (Pubitemid 44168485)
9. Seckinger P, Lowenthal JW, Williamson K, Dayer JM, MacDonald HR. A urine inhibitor of interleukin-1 activity affects both interleukin-1 alpha and 1 beta but not tumor necrosis factor alpha. J Immunol 1987; 139: 1546-1549 (Pubitemid 17151587)
10. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin-1 receptor antagonist (IL-1ra) is an acute-phase protein. J Clin Invest 1997; 99: 2930-2940 (Pubitemid 27278670)
11. Strandberg L, Lorentzon M, Hellqvist A, et al. Interleukin-1 system gene polymorphisms are associated with fat mass in young men. J Clin Endocrinol Metab 2006; 91: 2749-2754 (Pubitemid 44026381)
12. Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 2002; 87: 1184-1188
13. Juge-Aubry CE, Somm E, Giusti V, et al. Adipose tissue is a major source of interleukin-1 receptor antagonist. Diabetes 2003; 52: 1104-1110
14. Somm E, Cettour-Rose P, Asensio C, et al. Interleukin-1 receptor antagonist is up-regulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia 2006; 49: 387-393 (Pubitemid 43185409)
15. Hosoi T, Okuma Y, Nomura Y. Leptin induces IL-1 receptor antagonist expression in the brain. Biochem Biophys Res Commun 2002; 294: 215-219 (Pubitemid 34694079)
16. Luheshi GN, Gardner JD, Rushforth DA, Loudon AS, Rothwell NJ. Leptin actions on food intake and body temperature are mediated by IL-1. Proc Natl Acad Sci USA 1999; 96: 7047-7052
17. Matsuki T, Horai R, Sudo K, Iwakura Y. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med 2003; 198: 877-888 (Pubitemid 37152925)
18. Somm E, Henrichot E, Pernin A, et al. Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes 2005; 54: 3503-3509 (Pubitemid 43334342)
19. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860 (Pubitemid 35050963)
20. Ehses JA, Perren A, Eppler E, et al. Increased number of isletassociated macrophages in type 2 diabetes. Diabetes 2007; 56: 2356-2370 (Pubitemid 47358243)
21. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39: 1005-1029
22. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986; 332: 1545-1547 (Pubitemid 16061563)
23. Maedler K, Spinas GA, Lehmann R, et al. Glucose induces beta-cell apoptosis via up-regulation of the Fas receptor in human islets. Diabetes 2001; 50: 1683-1690 (Pubitemid 33641583)
24. Maedler K, Størling J, Sturis J, et al. Glucose- and interleukin- 1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 2004; 53: 1706-1713 (Pubitemid 38857028)
25. Maedler K, Sergeev P, Ehses JA, et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci USA 2004; 101: 8138-8143 (Pubitemid 38698067)
26. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526 (Pubitemid 46588416)
27. Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K. The anti-inflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 2008; 149: 2208-2218 (Pubitemid 351574505)
28. Boulay JL, O'Shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 2003; 19: 159-163
29. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374: 1-20. (Pubitemid 37046923)
30. Pedersen BK, Febbraio MA. Point: interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007; 102: 814-816
31. Mooney RA. Counterpoint: interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007; 102: 816-818
32. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200 (Pubitemid 27525539)
33. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273-2282 (Pubitemid 38535056)
34. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin-6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000; 85: 3338-3342 (Pubitemid 30944547)
35. Wallenius V, Wallenius K, Ahrén B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8: 75-79 (Pubitemid 34101732)
36. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL- 6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab 2004; 287: E182-7. (Pubitemid 38856299)
37. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-190 (Pubitemid 40321354)
38. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005; 146: 3417-3427
39. Stouthard JM, Oude Elferink RP, Sauerwein HP. Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes. Biochem Biophys Res Commun 1996; 220: 241-245
40. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 2003; 311: 372-379 (Pubitemid 37340087)
41. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003; 278: 45777-45784 (Pubitemid 37432722)
42. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003; 278: 13740-13746
43. Kim JH, Kim JE, Liu HY, Cao W, Chen J. Regulation of interleukin- 6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J Biol Chem 2008; 283: 708-715
44. Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev 2006; 12: 6-33.
45. Hiscock N, Chan MH, Bisucci T, Darby IA, Febbraio MA. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J 2004; 18: 992-994 (Pubitemid 39561502)
46. Bastard JP, Maachi M, Tran Van Nhieu J, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002; 87: 2084-2089 (Pubitemid 34521492)
47. Steensberg A, Fischer CP, Sacchetti M, et al. Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 2003; 548: 631-638 (Pubitemid 36527483)
48. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 2004; 53: 1643-1648 (Pubitemid 38864744)
49. Geiger PC, Hancock C, Wright DC, Han DH, Holloszy JO. IL-6 increases muscle insulin sensitivity only at superphysiological levels. Am J Physiol Endocrinol Metab 2007; 292: E1842-6. (Pubitemid 47084722)
50. Petersen EW, Carey AL, Sacchetti M, et al. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 2005; 288: E155-62. (Pubitemid 40023802)
51. van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 2003; 88: 3005-3010 (Pubitemid 36877463)
52. Franckhauser S, Elias I, Rotter Sopasakis V, et al. Overexpression of IL-6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 2008; 51: 1306-1316
53. Nieto-Vazquez I, Fernández-Veledo S, de Alvaro C, Lorenzo M. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes 2008; 57: 3211-3221
54. Ellingsgaard H, Ehses JA, Hammar EB, et al. Intereleukin-6 regulates α-cell mass expansion. Proc Natl Acad Sci USA 2004; 105: 13163-13168